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Abstract
Background. Adult attention-deficit/hyperactivity disorder (aADHD) is still a largely unrecog-
nized psychiatric condition despite its strong impact on individuals’ well-being. Here, we
describe the healthcare situation of individuals with incident aADHD over 4 years before and
4 years after initial administrative diagnosis.
Methods.A retrospective, longitudinal cohort analysis was conducted using German claims data.
The InGef database contained approximately 5millionmember-records from over 60 nationwide
statutory health insurances (SHI). Individuals were indexed upon initial diagnosis of aADHD.
Results. Average age at diagnosis of aADHD was 35 years, and 60% of individuals were male.
Comorbidities, resource use, and healthcare costs were substantial before initial diagnosis and
decreased within the 4 years thereafter. Only 32% of individuals received initial ADHD med-
ication and adherence was low. The majority received psychotherapy. Individuals with initial
ADHD medication showed the highest share in comorbidities, physician visits, medication use
for comorbidities, psychotherapy, and costs. Overall, healthcare costs were at over €4,000 per
individual within the year of aADHD diagnosis.
Conclusions. We conclude that earlier recognition of aADHD could prevent the development
and aggravation of comorbid mental illnesses. At the same time, comorbid conditions may have
masked (“over-shadowed”) aADHD and delayed diagnosis. The burden of disease in aADHD is
high, which was noticeable especially among individuals who received initial ADHD-
medication, suggesting that psychopharmacological treatment was mainly considered for the
most severely ill. We conclude that measures to facilitate access of aADHD patients to clinical
experts are required to improve reality of care in the outpatient setting.
Introduction
Attention-deficit/hyperactivity disorder (ADHD) is a common neurodevelopmental disorder
that often persists into adulthood and is then termed “adult ADHD” (aADHD). Over the last
years, aADHD has been increasingly recognized as an impairing mental health condition [1]. A
timely recognition of aADHD and initiation of treatment may, however, be compromised by a
lack of consensus among physicians regarding core aADHD symptoms and diagnostic pro-
cedures [2]. Accordingly, recent studies have shown that aADHD is still underdiagnosed as is
evident from the low administrative prevalence of aADHD in Germany (between 0.04% in 2007
[3] and 0.66% in 2019 [4–6]), compared to the population prevalence ranging between 1 and 7%
in high-income countries [7].
aADHD is a risk factor for various mental disorders [6,8,9]. The frequent occurrence of
comorbidities (“diagnostic over-shadowing”) is a factor that may lead tomisdiagnoses or delayed
diagnosis, and in turn delay treatment. A recent study based on statutory health insurance (SHI)
claims data has shown that adults with ADHD show significantly higher medical costs than those
without, due to ADHD and associated comorbidities [6]. It is possible that early detection and
treatment initiation of aADHD reduce the burden of illness and improve the quality of life of
those affected, because the development of comorbidities may be prevented [10–12]. The
resulting decrease in healthcare resource use and avoided comorbidities may lead to long-term
cost savings.
Research on the impact of aADHD diagnosis, therapies, and the development of costs is,
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individuals with incident aADHD, based on German SHI claims
data. Our longitudinal study analyzed the trajectory of aADHD 4
years before and after diagnosis.
Method
Study design and participants
SHI claims data study
The analysis was conducted using German claims data from the
InGef research database, containing approximately 5 million anon-
ymized member-records from over 60 nationwide SHIs. The sam-
ple is representative of the German population in terms of age and
sex, and it is widely used for real-world evaluation. There is a good
overall accordance of the database with the German population in
terms of morbidity, mortality, and drug usage [13].
The study was designed to capture individuals with incident
aADHD, hence individuals who receive an initial diagnosis of
ADHD as adults and who have not yet received treatment. The
study was conducted as a longitudinal cohort design study. Data
were available from 2012 to 2017. Individuals with aADHD were
identified between 2013 and 2017 upon documented diagnosis of
ICD-10 GM F90, including F90.0, F90.1, F90.8, F90.9, as a con-
firmed outpatient or inpatient (main or secondary) diagnosis.
Annual cohorts were built to allow a maximum observation period
of 4 years before (t 4, t 3, t 2, t 1) and after diagnosis (t+1, t
+2, t+3, t+4) with each year of observation as 365 days, Figure 1.
The first year of follow-up (t+1) comprises the quarter of index,
in which the initial aADHD diagnosis was documented, and the
subsequent three-quarters. Three exclusion criteria were applied.
First, individuals had to be continuously insured throughout 2012–
2017 to avoid loss to follow-up, also excluding 12 individuals who
died during observation. Second, to ensure incident aADHD, no
documented ADHD diagnosis or prescription of ADHD-specific
medication was allowed at minimum 365days before index (cohort
2013) to a maximum of 1,460 days before index (cohort 2016).
Third, individuals had to be between 18 and 55 years of age; for
example, an individual with index in 2013 had to be at least 19 years
and atmaximum51 years at index. Incident adults above 55 years of
age were excluded to prevent bias in older age groups due to the
overall high morbidity after this age. Applying these criteria, 2,380
individuals with incident aADHD out of 3,129,423 continuously
insured individuals were eligible.
The aADHD population was stratified according to the prescrip-
tion of ADHD-specific medication within t+1 Figure 1. Individuals
with at least two prescriptions within t+1 were classified as
“initial ADHD medication,” while individuals with no or only one
prescription were classified as “no initial ADHDmedication.”Here,
we considered the issuing of at least two prescriptions as an indica-
tion for initiation of a specific, longer-term ADHD medication
treatment. Individuals were kept in their assigned subgroup
irrespective of subsequent ADHD medication status. A maximum
of 5% of those assigned to “no initial ADHD medication” in t+1
received more than one prescription in t+2, t+3, and t+4.
Outcomes and statistical analyses
Basic demographic information (age, sex) was extracted for all
identified individuals with aADHD. Outcomes measured were:
speciality of the diagnosing physician, physician visits during
observation; speciality of the initial prescriber of ADHD-specific
medication; predefined comorbidities commonly associated with
aADHD; prescription of disorder-specific medication, psychother-
apy, hospitalization, healthcare costs, sickness benefits, and sick
leave days. In Germany, sickness benefits funded by the SHI are
available after more than 6weeks of continuous inability to work.
Prior to that the employer continues salary payment, which is not
observable within this dataset. The amount of sickness benefits is
calculated based on the regular income. Sick leave days are defined
as all days a person is not able to work based on doctor’s note. Sick
leave days are documented independently of sickness benefits.
Office-based physicians were classified according to their med-
ical speciality based on AGS (physician speciality code): “GP”
(general practitioner) AGS 1, 2, 3. “Psych MD” was used for
physicians practicing as psychiatrists and medical psychotherapists
(AGS 47, 51, 53, 58, 60, 61). “Psych” was used for psychological
psychotherapists (AGS 68, 69). Psychotherapy (doctor’s fee scale
[“EBM”] chapter 35) and up to five probatory sessions before long-
term psychotherapy (EBM 35150, 30931) were assessed. The fol-
lowing psychiatric comorbidities were analyzed via ICD-10 GM:
substance use disorders (SUD) (F10–F19); mood disorders
(F30–F39); anxiety disorders (F40–F48); personality and behav-
ioral disorders (F60–F69) and all mental and behavioral disorders
(F00–F99). Medication was documented when handed in at the
pharmacy based on the anatomical-therapeutic-chemical classifi-
cation system (ATC). ADHD-specific medication: N06BA02
dexamphetamine, N06BA04 methylphenidate, N06BA09 atomox-
etine, N06BA12 lisdexamfetamine [14]; treatment of psychiatric
comorbidities: N05A antipsychotics, N05B anxiolytics, N05C
hypnotics and sedatives, N06A antidepressants, N07BB alcohol
Figure 1. Indexing of individuals with ADHD in yearly cohorts.
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dependence, N07BC opiate dependence. Note: inpatient
ADHD-specific medication was not visible within the database.
Healthcare costs (all-cause) were documented as follows:
healthcare costs total, inpatient care, outpatient care, psychother-
apy, medical aids and remedies, medication, and sickness benefits.
To adjust for high-cost cases, costs of individuals with healthcare
costs above the 95th percentile were replaced (winsorized) by the
upper cost limit of the 95th percentile. No individual was
excluded.
This study presents descriptive information of individuals
with aADHD 4 years before and 4 years after initial diagnosis
on the basis of yearly cohorts indexed in 2013, 2014, 2015, and
2016, with individual observation time pre-index and post-
index, see Figure 1. Tests for significance were conducted within
the cohorts indexed in the year 2014 and 2015, comparing t  2
and t+ 2 to t+ 1 for time-based comparisons; subgroup compar-
isons were done for t+ 1. Significance for comorbidities and
therapies was tested using Chi-square test. Outcomes tested
were: mental and behavioral disorders (any), mood disorders,
prescription of antidepressants, ADHD-specific medication,
hospitalization due to psychiatric primary indication, and psy-
chotherapy. In addition, odds ratios (OR) and 95% upper and
lower confidence intervals (95% CI) were calculated if applicable.
For cost comparisons, the Wilcoxon test was used. Outcomes
tested were: total healthcare costs and psychotherapy costs. In
addition, the statistical difference in age and sex between the
group of individuals with ADHD-medication and without was
tested using Student’s t test and Chi-square test, respectively. For
continuous variables reporting means, standard deviation
(SD) was given. For data storage and processing, Microsoft
Office Excel® 2010 (Microsoft Corporation, WA) and R
(Version Microsoft R Open 3.5.0) were used.
Ethical approval and data protection
The analysis did not involve any decisions regarding interventions
or the omission of interventions. Accordingly, institutional review
board/ethical approval and informed consent of the individual were
not required. Moreover, all individual patient data are de-identified
in the research database to comply with German data protection
regulations. Patient numbers below five were not reported.
Results
Demographic and clinical characteristics of the patient cohort
A study cohort of 2,380 individuals with incident aADHD was
identified, 60% being male and, on average, 35 years old at initial
aADHD diagnosis, Table 1. Age and sex were not statistically
significant between individuals with initial ADHD medication
and without. Most individuals received diagnosis from a specialist:
23% in the inpatient setting and another 33% by the outpatient
specialist (PsychMD); 41%were diagnosed by theGP. Themajority
of individuals with initial ADHD medication were diagnosed by
outpatient specialists (56%: 352 out of 624), whereas almost half of
the individuals without initial ADHD medication were diagnosed
by GPs (46%: 807 out of 1,756).
Three-quarters of the study population were categorized as
individuals without initial ADHD-specific medication (74%:
1,756 out of 2,380) and one-quarter was categorized as individuals
with initial ADHD medication as they had received at least two
prescriptions within the year of initial aADHD diagnosis (26%:
624 out of 2,380). Overall, about a third (32%: 759 out of 2,380)
received at least one prescription of ADHD-specific medication in
the year of initial aADHD diagnosis. ADHD-specific medication
was prescribed mostly (69%: 526 out of 759) by the outpatient
Table 1. Demography, diagnosing physician, and prescriber of ADHD-specific medication.
Age and sexa ADHD total Initial ADHD medication No initial ADHD medication
Total, n (%) 2,380 (100%) 624 (26%) 1,756 (74%)
Female, n (%) 961 (100%) 267 (28%) 694 (72%)
Male, n (%) 1,419 (100%) 357 (25%) 1,062 (75%)
Age (years) meanSD 34.6 9.9 34.9 9.3 34.6 10.2
Age difference initial ADHD medication vs. no medication p = 0.42
Sex difference initial ADHD medication vs. no medication p = 0.17
Diagnosing physician (speciality of office-based outpatient) and inpatient diagnosis of initial aADHD diagnosis at index quarter (no significance tested)
General practitioner 980 of 2,380 (41%) 173 of 624 (28%) 807 of 1,756 (46%)
Psych MD 778 of 2,380 (33%) 352 of 624 (56%) 426 of 1,756 (24%)
Psych 95 of 2,380 (4%) 17 of 624 (3%) 78 of 1,756 (4%)
Inpatient diagnosis 557 of 2,380 (23%) 178 of 624 (29%) 379 of 1,756 (22%)
Number of individuals with at least one prescription of ADHD-specific medication in the first year of follow-up
At least one prescription of ADHD-specific medication 759 of 2,380 (32%) 624 of 624 (100%) –
Prescribing physician of ADHD-specific medication (outpatient) for those with at least one prescription of ADHD-specific medication in the first year of follow-up
General practitioner 123 of 759 (16%) 78 of 624 (13%) –
Psych MD 526 of 759 (69%) 398 of 624 (64%) –
One individual may have multiple ADHD diagnoses and prescriptions from multiple physicians.
Abbreviation: ADHD, attention-deficit/hyperactivity disorder.aTested outcomes: age and sex differences between individuals with initial ADHD-medication and no initial ADHD-medication. No
statistical difference between individuals with initial ADHD-medication and without concerning sex (Chi-square test; p = 0.17) and age (t test; p = 0.42) at index.
European Psychiatry 3
specialist, however, 16% (123 out of 759) of the individuals received
a prescription by the GP.
Psychiatric comorbidities before and after initial aADHD
diagnosis
All individuals had at least one diagnosis of mental and behavioral
disorders at index, including by definition aADHD (Table 2). After
index, the number of individuals who continued to receive a docu-
mented aADHD diagnosis decreased from 100 to 50% in year two,
43% in year three, and 39% in year four. The percentage of individuals
with any psychiatric diagnoses increased significantly from 50% 4
years before index to 100% at index (including aADHD) and
decreased significantly 4years after index to 72%. Individuals with
initial ADHDmedication showed significantly higher rates of psychi-
atric disorders than those without throughout the entire observation.
In the year of incident aADHDdiagnosis, 56% of the individuals
had documented anxiety disorders, 53%mood disorders, 20% SUD,
and 19% personality and behavioral disorders (Supporting Infor-
mation). For all these psychiatric comorbidities, an increase before
and decrease after index was observed. However, for mood disor-
ders in individuals with initial ADHDmedication, the percentage of
affected individuals was higher after index compared with before
index.
Therapies before and after initial aADHD diagnosis
In the year of initial aADHD diagnosis, 32% of individuals received
at least one prescription of ADHD-specific medication, which
decreased significantly to 13% within 4 years (Table 3). A significant
decrease was also observed for those with initial ADHD-medication:
4 years after index, less than half still received medication (41%).
In the total ADHD cohort, the most common co-medication was
antidepressants (36% of individuals in t+1). Before index, a signif-
icant increase and thereafter a decrease was observed. However,
more individuals continued to receive a prescription after index
compared with the time period before index. Throughout observa-
tion, the percentage of individuals receiving antidepressants was
significantly higher in the subgroup “initial ADHD-medication”
compared to the subgroup “no initial ADHD medication.” For all
other classes of co-medication analyzed, a prescription peak was
observed in the year of the index: 10% of individuals received
antipsychotics, 6% hypnotics and sedatives, and 4% anxiolytics.
Medication for SUDwas not reported due to data protection (n<5).
Table 2. Specific psychiatric comorbidities before and after initial aADHD diagnosis.
t  4 t  3 t  2 t 1 t + 1 t + 2 t + 3 t + 4
Number of individuals observable before and after index (yearly cohorts)
ADHD total (N) 535 1,032 1,648 2,380 2,380 1,845 1,348 732
Initial ADHD medication (N) 165 310 463 624 624 459 314 161
No initial ADHD medication (N) 370 722 1,185 1,756 1,756 1,386 1,034 571
Documentation of ADHD in study cohort throughout observation (no significance tested)
At least one diagnosis of ADHD documented – – – – 2,380 (100%) 929 (50%) 574 (43%) 285 (39%)
Individuals with at least one diagnosis of mental and behavioral disorders (any)a
ADHD total 269 (50%) 576 (56%) 978 (59%) 1,541 (65%) 2,380 (100%) 1,558 (79%) 997 (74%) 526 (72%)
Initial ADHD medication 91 (55%) 202 (65%) 301 (65%) 458 (73%) 624 (100%) 429 (93%) 273 (87%) 136 (84%)
No initial ADHD medication 178 (48%) 374 (52%) 677 (57%) 1,083 (62%) 1,756 (100%) 1,029 (74%) 724 (70%) 390 (68%)
Increase pre-index p < 0.001; OR not calculated as every individual has ADHD in t + 1
Decrease post-index p < 0.001, OR not calculated as every individual has ADHD in t + 1
No initial vs. initial ADHD medication p < 0.001, OR not calculated as every individual has ADHD in t + 1
Individuals with at least one diagnosis of mood disordera
ADHD total 170 (32%) 330 (32%) 565 (34%) 940 (39%) 1,265 (53%) 849 (46%) 584 (43%) 291 (40%)
Increase pre-index p < 0.001; OR 2.17; 95% CI [1.91–2.48]
Decrease post-index p < 0.001; OR 0.75; 95% CI [0.66–0.85]
Initial ADHD medication 64 (39%) 124 (40%) 213 (46%) 311 (50%) 405 (65%) 277 (60%) 177 (56%) 85 (53%)
Increase pre-index p < 0.001; OR 2.17; 95% CI [1.68–2.80]
Decrease post-index p = 0.141; OR 0.82; 95% CI [0.64–1.06]
No initial ADHD medication 106 (29%) 206 (29%) 352 (30%) 629 (36%) 860 (49%) 572 (41%) 407 (39%) 206 (36%)
Increase pre-index p < 0.001; OR 2.27; 95% CI [1.94–2.66]
Decrease post-index p < 0.001; OR 0.73; 95% CI [0.63–0.85]
No initial vs. initial ADHD medication p < 0.001; OR 0.52; 95% CI [0.43–0.63]
Different sample sizes during observation due to yearly cohorts—see “Methods.”
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CI, confidence intervals; OR, odds ratio.aOutcome tested: (any) mental and behavioral disorders and mood disorder; Odds Ratios
not calculated for (any)mental and behavioral disorders as every individual has at least onemental and behavioral disorder in t + 1 (ADHD). Significance tested based on Chi-square test; for time-
wise comparison: increase t  2 to t + 1 and decrease t + 1 to t + 2; for group comparison: initial ADHD-medication to no initial ADHD-medication compared at t + 1.
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Table 3. Specific medication therapy and psychotherapy before and after initial aADHD diagnosis.
t  4 t  3 t  2 t 1 t + 1 t + 2 t + 3 t + 4
Number of individuals observable before and after index (yearly cohorts)
ADHD total (N) 535 1,032 1,648 2,380 2,380 1,845 1,348 732
Initial ADHD medication (N) 165 310 463 624 624 459 314 161
No initial ADHD medication (N) 370 722 1,185 1,756 1,756 1,386 1,034 571
Individuals with at least one ADHD-specific prescriptiona
ADHD total – – – – 759 (32%) 358 (19%) 198 (15%) 98 (13%)
Decrease post-index p < 0.001; OR 0.52; 95% CI [0.45–0.60]
Initial ADHD medication – – – – 624 (100%) 293 (64%) 145 (46%) 66 (41%)
Decrease post-index p < 0.001; OR 0.003 95% CI [0.00–0.02]
Individuals with at least one antidepressants prescriptiona
ADHD total 121 (23%) 234 (23%) 390 (24%) 656 (28%) 852 (36%) 511 (28%) 341 (25%) 183 (25%)
Increase pre-index p < 0.001; OR 1.80; 95% CI [1.56–2.08]
Decrease post-index p < 0.001; OR 0.68; 95% CI [0.60–0.78]
Initial ADHD medication 47 (28%) 87 (28%) 146 (32%) 235 (38%) 268 (43%) 152 (33%) 97 (31%) 54 (34%)
Increase pre-index p < 0.001; OR 1.64; 95% CI [1.27–2.14]
Decrease post-index p = 0.001; OR 0.65; 95% CI [0.50–0.85]
No initial ADHD medication 74 (20%) 147 (20%) 244 (21%) 421 (24%) 584 (33%) 359 (26%) 244 (24%) 129 (23%)
Increase pre-index p < 0.001; OR 1.93; 95% CI [1.62–2.30]
Decrease post-index p < 0.001; OR 0.70; 95% CI [0.60–0.82]
No initial vs. initial ADHD medication p < 0.001; OR 0.66; 95% CI [0.54–0.80]
Individuals with at least one psychotherapy sessiona
ADHD total 187 (35%) 378 (37%) 627 (38%) 1,088 (46%) 1,483 (62%) 794 (43%) 509 (38%) 257 (35%)
Increase pre-index p < 0.001; OR 2.70; 95% CI [2.36–3.07]
Decrease post-index p < 0.001; OR 0.46; 95% CI [0.40–0.52]
Initial ADHD medication 63 (38%) 133 (43%) 203 (44%) 350 (56%) 466 (75%) 245 (53%) 140 (45%) 69 (43%)
Increase pre-index p < 0.001; OR 3.77; 95% CI [2.90–4.93]
Decrease post-index p < 0.001; OR 0.39; 95% CI [0.30–0.51]
No initial ADHD medication 124 (34%) 245 (34%) 424 (36%) 738 (42%) 1,017 (58%) 549 (40%) 369 (36%) 188 (33%)
Increase pre-index p < 0.001; OR 2.47; 95% CI [2.12–2.88]
Decrease post-index p < 0.001; OR 0.48; 95% CI [0.41–0.55]
No initial vs. initial ADHD medication p < 0.001; OR 0.47; 95% CI [0.38–0.57]
Individuals with at least one visit at the Psych MD (no significance tested)
ADHD total 119 (22%) 238 (23%) 384 (23%) 731 (31%) 1,326 (56%) 667 (37%) 453 (34%) 221 (30%)
Initial ADHD medication 51 (31%) 90 (29%) 149 (32%) 255 (41%) 510 (82%) 271 (59%) 154 (49%) 72 (45%)
No initial ADHD medication 68 (18%) 148 (20%) 235 (20%) 476 (27%) 816 (46%) 406 (29%) 299 (29%) 149 (26%)
Individuals with at least one visit at the Psych (no significance tested)
ADHD total 49 (9%) 88 (9%) 176 (11%) 308 (13%) 467 (20%) 277 (15%) 166 (12%) 68 (9%)
Initial ADHD medication 23 (14%) 42 (14%) 70 (15%) 108 (17%) 161 (26%) 100 (22%) 54 (17%) 22 (14%)
No initial ADHD medication 26 (7%) 46 (6%) 106 (9%) 200 (11%) 306 (17%) 177 (13%) 112 (11%) 46 (8%)
Different sample sizes during observation due to yearly cohorts—see “Methods.”
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; CI, confidence intervals; OR, odds ratio.
aSignificance tested based on Chi-square test; for time-wise comparison: increase t  2 to t + 1 and decrease t + 1 to t + 2; for group comparison: initial ADHD-medication to no initial ADHD-
medication compared at t + 1.
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Sixty-two percent of individuals received psychotherapy at t+ 1,
and around 30% in the years before and after index. Again, indi-
viduals with initial ADHD medication showed higher percentages
throughout observation with a peak at index (initial ADHD med-
ication: 75%; no initial ADHD medication 58%). 20–30% of the
individuals with psychotherapy only had probatory sessions (sup-
plement). Around three-quarters of the individuals consulted a
specialist in the year of aADHD diagnosis (56% Psych MD, 20%
Psych). The percentage was higher for individuals who received
initial ADHD medication than those who did not (Psych MD 82%
vs. 26%, Psych: 46% vs. 17%;). The number of individuals increased
before index and decreased thereafter; however, more individuals
consulted specialists after index than before. Independent of the
initial medication regime, around 90% of the individuals attended
the GP throughout the entire observational period (supplement).
Hospitalizations, also due to psychiatric reasons, peaked at index
and decreased thereafter, however, increased again in t+ 4 for those
with initial ADHD-medication (supplement).
Healthcare costs before and after initial aADHD diagnosis
In t + 1, healthcare costs were, on average, €4,006 per individual
(Supporting Information). In the years before index, an increase in
costs was observed, peaking at t+1, but decreased again afterward,
reaching a level similar to the years before diagnosis. Main cost
drivers at index were psychotherapy (€2,772), inpatient (€1,747),
and outpatient care (€1,276).While most costs after index decreased
to a similar level as before, the costs for psychotherapy were around
twice as high 4 years after index compared with 4 years before index.
For individuals with and without initial ADHDmedication, the
costs peaked at t+1 (€5.442 and €3.485), with a significant increase
before diagnosis and decrease thereafter, Table 4. For those with
initial ADHDmedication, the costs increased again in t+4. In both
subgroups, the main cost drivers were similar to the overall cohort.
Especially, psychotherapy was a relevant cost factor for individuals
with initial ADHD medication even before index. However, costs
were notably higher throughout all years of observation for all cost
categories and for individuals with initial ADHDmedication com-
pared to those without.
Sickness benefits and sick leave days were notably elevated for all
incident aADHD individuals in the year of initial aADHD diagno-
sis, peaking already in t 1. They were especially elevated for those




In this statutory health claims data analysis, we described disease
burden, treatment allocation, and healthcare costs for 2,380 indi-
viduals over 4 years before and after the initial aADHD diagnosis.
Table 4. Direct healthcare costs [€], sickness benefits [€], and sick leave days [days] before and after initial aADHD diagnosis—comparison of cohorts with initial and
without initial ADHD medication.
t  4 t  3 t 2 t  1 t + 1 t + 2 t + 3 t + 4
Initial ADHD medication (meanSD)
Total healthcare
costsa
2,647  5,234 2,803  4,494 2,775  4,475 3,951  6,099 5,442  6,195 3,818  4,375 3,514  4,750 4,144  6,137
Inpatient care 1,233  4,624 1,481  4,687 1,072  3,457 1,493  4,415 1,884  4,777 1,231  4,229 1,414  4,890 1,940  5,833
Outpatient care 732  823 886  881 897  882 1,182  1,161 1,932  1,662 1,565  1,449 1,221  1,148 1,054  1,011
Psychotherapya 1,350  3,649 1,791  5,276 1,167  3,034 2,172  5,189 4,580  9,750 3,927  9,503 2,509  7,392 1,727  5,229
Aids and remedies 87  216 117  265 114  273 135  329 198  485 195  497 177  449 171  392
Medication 222  395 225  381 272  460 300  515 827  771 658  745 564  732 541  744
Sickness benefit 388  2,524 336  2,628 406  2,737 878  4,222 483  2,456 225  1,600 553  3,875 515  3,606
Sick leave days
(days)
21  99 18  58 23  85 39  114 21  71 18  55 19  71 21  76
No initial ADHD medication (mean  SD)
Total healthcare
costsa
1,599  2,508 1,550  2,294 1,941  3,152 2,142  3,510 3,485  5,001 2,323  3,473 2,108  3,098 1,785  2,732
Inpatient care 890  3,111 706  2,561 916  3,005 884  3,073 1,700  4,472 957  3,053 863  2,547 746  2,856
Outpatient care 550  591 584  608 637  672 735  795 1,072  990 839  917 769  821 673  758
Psychotherapya 597  2,129 512  1,742 942  3,347 1,400  4,425 2,234  5,658 1,727  5,807 1,587  5,707 1,266  4,847
Aids and remedies 83  219 94  247 95  231 96  257 122  287 110  259 111  271 128  380
Medication 192  420 178  381 165  331 169  315 233  382 220  399 211  376 195  360
Sickness benefit 163  1,306 119  1,084 246  1,604 370  2,316 475  2,505 251  1,776 210  2,041 220  2,004
Sick leave days
(days)
13  43 13  48 17  59 20  66 20  64 15  49 13  44 15  55
Abbreviations: ADHD, attention-deficit/hyperactivity disorder; SD, standard deviation.
aOutcomes tested were: total healthcare costs and costs for psychotherapy. Significance tested based on Wilcoxon test; increase t  2 to t + 1 and decrease t + 1 to t + 2; for group comparison:
“initial ADHD-medication” to no “initial ADHD-medication” compared at t + 1; all tests were significant at a level of p < 0.001.
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In the years before aADHD diagnosis, psychiatric comorbidities,
disorder-specificmedication (primarily antidepressants), and psycho-
therapy increased, peaking in the year of diagnosis. A similar pattern
was observed for healthcare costs. However, the number of sick leave
days and sickness benefits peaked in the year before diagnosis.
Most individuals received diagnosis from a specialist: 23% in the
inpatient setting and another 33% by the outpatient specialist
(Psych MD); 41% were diagnosed by the GP. In the year of
diagnosis, 76% of individuals had a consultation with a specialist
for CNS disorders, decreasing to 39% in t+4. Over the years
following initial diagnosis, the prevalence of psychiatric comorbid-
ities and prescriptions of disorder-specific drugs, especially antide-
pressants, psychotherapy, and healthcare costs decreased again but
were higher compared with levels observed in the years before
diagnosis. Moreover, the proportion of individuals who continued
to receive an aADHD diagnosis decreased to 39% in t+ 4.
In the year of initial diagnosis, 32% of individuals received at least
one, and 26% at least two prescriptions of ADHD-specific medica-
tion. Specialists for CNS disorders (psychiatrists) prescribedADHD-
specific medication in most cases (69%). Four years after diagnosis,
only 13% of individuals received ADHD-specific medication.
Throughout observation, comorbidities, corresponding medi-
cation, psychotherapy, healthcare costs, sickness benefit, and sick
leave days were more frequent in individuals with initial ADHD
medication than those without, suggesting a higher disease burden.
Healthcare costs, costs for inpatient care, sick leave days, and
sickness benefits in this subgroup initially decreased in the first 2
years following diagnosis of aADHDbut tended to increase again in
t+3 and t+4.
Interpretation of findings
ADHD is a neurodevelopmental disorder beginning in childhood
or early adolescence. It often persists into adulthood with different
trajectories over the lifespan [15]. It has been suggested that cases of
“late-onset ADHD” might exist (>12 years) but are probably
restricted to only few cases [1,16]. Thus, we did not expect to find
a rather advanced average age of 35 years in our dataset.
ADHD has long been considered a “childhood disorder,” and
recent findings suggest that there is still a significant lack of con-
sensus among psychiatrists and other physicians with respect to
core symptoms and valid diagnostic procedures for aADHD, leav-
ing the disorder underdiagnosed [2,17]. Here, less than 50% of
individuals had a consultation with a psychiatrist or psychologist in
the years before the initial aADHD diagnosis. Accordingly,
aADHD was possibly not recognized or misdiagnosed over a
prolonged period in a relevant proportion of individuals, especially
as comorbidities may mask ADHD symptoms, complicate, and
delay diagnosis [6,18,19].
Increasing comorbidities and use of disorder-specific medica-
tion, psychotherapy, and healthcare costs suggest a steadily increas-
ing symptom burden in individuals over the years before aADHD is
diagnosed. It has been shown that a time delay in diagnosis of
aADHDmay lead to an onset or deterioration of various psychiatric
comorbidities [20–22]. Assuming that in the sample investigated
here the underlying ADHD condition was present but not recog-
nized, we suggest that disease burden increased over the years as a
result of inappropriate or insufficient interventions with respect to
the underlying condition.
In line with previous investigations into the healthcare situation
for adults with ADHD [5], the GP plays an important role as the
diagnosing physician, as 41% of individuals were initially diagnosed
by a GP. However, ADHD-specific medication was primarily pre-
scribed by psychiatrists or in the inpatient setting.
An important finding of the present investigation is that in the
year of initial diagnosis, less than one-third of individuals received
any prescription of ADHD-specific medication, and only a fourth
got at least two prescriptions. At the same time, almost two-thirds
of individuals received psychotherapy in the year of aADHD diag-
nosis. In about one-third of individuals, psychotherapy had been
initiated already before diagnosis of aADHD, presumably for treat-
ment of comorbid disorders. Guidelines in practice during the
observational period of the present investigation recommended a
dual treatment approach with stimulant medication and psycho-
therapy as the first choice [23]. In current German guidelines,
ADHD-specific medication is recommended as the first choice also
in mild and moderate cases of aADHD, along with psychoeduca-
tion [14]. Apparently, despite the vast body of evidence for the
beneficial effects of ADHD-specific medication, at least in the
short-term [24], and in contrast to the recommendation in previous
and current guidelines, stimulant medication is only reluctantly
prescribed in newly identified adults with ADHD. Moreover, sig-
nificantly higher comorbidities, healthcare costs, and sick leave
days in individuals with initial ADHD medication compared to
those without suggest that medication is preferentially initiated in
individuals with a pronounced and heavier disease burden.
After aADHD diagnosis, psychiatric comorbidities, medication
use, utilization of psychotherapy, and total healthcare costs gener-
ally decreased to levels observed in the years before diagnosis. Only
half of the individuals still received a clinical diagnosis of aADHDat
t+2, and counts continued to decrease. A similar trend was
recorded for prescriptions of ADHD-specific medication. These
trends may indicate some improvement of the psychiatric condi-
tions in individuals following diagnosis and initiation of treatment
for aADHD. Thus, it is possible that some individuals did not wish
or require to receive further treatment.
However, in patients with a higher disease burden, healthcare
costs, costs for inpatient care, and sick leave days tended to increase
again in t+ 3 and t+4, indicating a deterioration of the psychiatric
conditions. Almost all individuals had a consultationwith an expert
of CNS disorders in the year of diagnosis, but this proportion
steadily decreased to only about 60% in t+4. At the same time, less
than half still received a prescription of ADHD-specific medication
at year four. The intensity of healthcare utilization decreased in this
subgroup, whichmay have compromised more favorable outcomes
over a prolonged period.
Interestingly, healthcare utilization in the years after aADHD
diagnosis decreased considerably for the population investigated
here, and healthcare costs, comorbidities, medication use, and
disease burden as indicated by sick leave days generally returned
to but did not fall below pre-diagnostic levels. This, however, would
be expected if treatment initiated after aADHD diagnosis did not
merely lead to a transient mitigation of a slowly deteriorating
situation, but to a substantial improvement of the overall psychi-
atric conditions of individuals. Thus, a relevant proportion of
individuals may not be satisfied with the care they receive in the
outpatient setting, stop making appointments with the treating
physician, and drop out of the medical system, even though the
medical condition would necessitate continuation of care.
In a large clinical trial, initiation of a comprehensive, multi-
modal ADHD-specific treatment program over 1 year has been
shown to effectively reduce ADHD core symptoms and improve
functionality in aADHD [25]. These beneficial effects were main-
tained over another 1.5 years following the controlled phase of the
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study, demonstrating that treatment according to guidelines for at
least 1 year can be very effective in the long-term [26].
Overall, our findings suggest that significant deficiencies may
currently exist with respect to the reality of healthcare for aADHD
in Germany, and that guideline recommendations are not yet
comprehensively implemented in everyday routine care. We argue
that lack of experience with aADHD may represent one explana-
tion, highlighting the necessity for more educational programs on
this disorder for experts of CNS disorders and GPs. GPs apparently
are a major initial contact point and conduct in many cases an
initial clinical evaluation of psychiatric conditions. Accordingly,
medical education, and a close cooperation between specialities is
essential.
We suggest that the establishment of regional centers specializ-
ing in the management of aADHD may represent a promising
measure to improve the healthcare situation in the outpatient
setting. These centers would act as a central point of contact for
physicians and individuals with aADHD, offering physicians the
opportunity to refer their individuals directly to ADHD specialists.
There, individuals could be evaluated and, upon confirmation of
the diagnosis, specific treatment measures would be initiated
according to guideline recommendations. Avoiding a delay of the
diagnosis and initiating a multimodal treatment program, tailored
to the individual needs, could reduce escalation of the disease
burden, and consequently healthcare costs [27,28]. In addition,
these centers can act as a supervisory body overseeing, managing,
and improving the reality of care through intersectoral collabora-
tion while also saving resources within the healthcare system.
Strengths and limitations
This study’s major strength is the longitudinal design, that is the
availability of data covering 4 years before and 4 years after the
initial diagnosis of aADHD. In addition, the multitude of available
endpoints within this representative sample of the German popu-
lation [13] provides valuable insights into the reality of care and
costs as experienced by individuals with aADHD.
In this study, we set out to analyze adults with initial ADHD,
who did not show prevalent diagnosis at least 365 days prior to the
initial adult ADHD diagnosis. By doing so, we excluded individuals
with continuous diagnoses of ADHD throughout early adulthood.
This may bias our cohort toward individuals who are not within
optimal care throughout early adulthood [4,6]. In addition, only
documented aADHD cases could be analyzed, which may bias our
study population toward individuals withmore severe symptoms of
aADHD or with psychiatric comorbidities seeking out professional
help. Furthermore, individuals may have received diagnosis of
ADHD in childhood, which could not be analyzed within the
6-year timeframe of our study. This study is based on SHI claims
data, which are recorded for the primary purpose of billing. Thus,
this source of data is limited in terms of primary information by
physicians and individuals themselves and does not depict costs
when paid out-of-pocket.
Conclusion
We conclude that adult individuals with ADHD in the current
German healthcare system may be recognized too late, misdiag-
nosed due to comorbid conditions masking ADHD symptoms, or
only diagnosed rather late in mid-adulthood, even though disease
burden is high. Following diagnosis,most individuals do not receive
continuous professional medical care for time periods exceeding 1
year. Interventions, especially ADHD-specific medication, are not
initiated as recommended in guidelines, and the overall effective-
ness of routine clinical care to ameliorate disease burden associated
with aADHD is limited. Regional centers specializing in ADHD
could provide a central point of contact for outpatient physicians
and individuals, which could be an effectivemeasure to improve the
reality of care.
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